

## **Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

## **Listing of Claims:**

**Claim 1** (currently amended): A pharmaceutical preparation which comprises 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid or a pharmacologically acceptable salt thereof in combination with ~~N-[2-cyano-4-(2,2-dimethyl-propylamino)-pyrimidin-5-ylmethyl]-4-(4-methyl-piperazin-1-yl)-benzamide~~ N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide or a pharmacologically acceptable salt thereof for simultaneous, sequential or separate use.

**Claim 2** (currently amended): The pharmaceutical preparation according to claim 1 ~~wherein its use is for the treatment of malignant diseases, bone metastasis, cancer cell growth, or/and cancer therapy-induced bone loss.~~

**Claim 3** (previously presented): A method of treating a patient suffering from bone metastasis, comprising administering to the patient an effective amount of the pharmaceutical preparation according to claim 1.

**Claim 4** (canceled)

**Claim 5** (currently amended): A pharmaceutical composition which comprises 2-(imidazol-1-yl)-1 hydroxyethane-1-1-disphosphonic acid or a pharmacologically acceptable salt thereof in combination with ~~comprising zoledronic acid and a cathepsin K inhibitor for the inhibition of bone metastasis, cancer cell growth or/and inhibition of cancer therapy-induced bone loss. or~~ a pharmacologically acceptable salt thereof for simultaneous, sequential or separate use wherein the cathepsin K inhibitor is selected from the group consisting of N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide.

**Claims 6-7** (canceled)

**Claim 8** (new)      The pharmaceutical preparation according to claim 1 wherein the pharmacologically acceptable salt of N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-[4-(1-propyl)-piperazin-1-yl]-benzamide is hydrogen maleate.